Stuart Baxter

Activist Investor Galloway Capital Partners Buys 6.01% of Noodles & Company "The filing further said that Galloway “intends to engage the board and management” regarding share performance, operations, management, governance — including potential changes to the board of directors — conflicted party transactions, capital allocation policies, and strategy." #activistinvesting #shareholderactivism #corporategovernance https://lnkd.in/gJr3tFgJ

2

TechStrat client Integra Medical Consulting receives strategic investment from MDpanel MDpanel, backed by Aquiline, has continued to expand internationally through a strategic investment in Canadian firm Integra. Integra is a technology enabled medical evaluation (IME) provider based in Vancouver, British Columbia. This milestone marks MDpanel’s second expansion within Canada, but the first conducting full IMEs. It represents a significant step forward in MDpanel’s mission to elevate access to high-quality medical opinions across North America. For almost a decade, Integra has built a strong reputation in Canada for its expert medical professional network, commitment to objectivity, and high-touch service model. By partnering with Integra, MDpanel deepens its reach into the Canadian market while remaining focused on delivering timely, objective, and high-quality medical opinions. Read more: https://lnkd.in/eUmgHi7g

11

1 Comment

Every capital loss I’ve seen started with one mistake. Someone trusted what they should have verified. Starnor Weise and I learned this the expensive way. A single approval pause triggered by one insecure stakeholder froze progress long enough to eat the margin and double holding costs. Not a market shock. A human one. Most developers treat discipline like style. Investors treat it like cushioning. We treat it like control. Because the real failure modes are predictable. A consultant who misses a regulatory tweak. A contractor who cannot fund mobilisation. A partner with off-paper veto power. These are governance cracks that turn clean models into capital calls. This is why our co-investment model is built around verification, not trust. Verified liquidity. Mapped authority. Rule-based cash flow. If the structure cannot hold pressure, it is not a co-investment. It is exposure. Discipline costs time and confrontation. Good. That friction is what stabilises cash flow in a city where informal decisions often outrun formal ones. Our rule is blunt. If we cannot lock the discipline mechanics, we do not lead. We verify liquidity, not intent. We map power, not titles. We run money by rule, never by trust. If any of that fails, the deal is noise. Which part of your deal process would collapse the moment you replaced trust with verification?

24

7 Comments

Big changes hit the global biopharma landscape last year, most notably a shift toward M&A and in-licensing over traditional IPOs. Our Corporate Transactions Group analyzed how the market is evolving and the outlook for this year in the 2026 Biopharma M&A and VC insights report. Download the report here: https://okt.to/0TFbmV #LifeSciences #Biopharmaceuticals #Healthcare #CorporateTransactionsGroup

7

👉️ Private Equity: Growth Jetpack or Identity Crisis? Taking PE money can feel like leveling up—or letting go. On one hand, you get capital, connections, and operational horsepower to scale faster than ever. On the other, you might be giving up more than just equity—like autonomy, culture, or the long-game vision you’ve been building. This blog breaks down the real trade-offs of partnering with PE: 🔍 When it accelerates growth ⚠️ When it introduces friction 🧠 How to avoid being sidelined post-deal 🤝 What alignment actually looks like ✅ And how to walk away with both capital and control If you’re considering outside investment—or advising someone who is—this is a must-read. Question for founders: If you’ve worked with a PE partner, what was your biggest win—or biggest surprise? #PrivateEquity #FounderLife #MergersAndAcquisitions #StartupExit #ScaleUp #BusinessGrowth #Entrepreneurship #CapitalRaising #Leadership #DealMaking

1